文献速递脊柱关节炎其他结缔组织病

替尔泊肽与生物制剂同步起始改善肥胖银屑病关节炎患者报告结局

Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.
PubMed 文献 · RMD Open · 2026-07-30

6个月时替尔泊肽组PsAID-12 PASS、HAQ≤0.5及PASI≤1达标率均显著更高,BMI与CRP降幅更大。

要点

  • 同步替尔泊肽与生物制剂可显著提高肥胖PsA患者6个月PsAID-12 PASS达标率。
  • 替尔泊肽组HAQ≤0.5与PASI≤1达标率显著优于单用生物制剂组。
  • 替尔泊肽组BMI与CRP下降幅度显著大于对照组。

核心结论

  • 肥胖PsA患者同步起始替尔泊肽与生物制剂,6个月时患者报告结局、皮肤控制、基线校正后关节疾病活动度及CRP降低均显著更优。

研究设计与样本

  • 替尔泊肽用法为2.5 mg/周,1个月后上调至5 mg/周。
  • 匹配变量包括BMI、疾病病程、DAPSA和PASI。

主要发现

  • 替尔泊肽组BMI变化为-2.9±2.0 kg/m²,对照组为+0.4±1.2 kg/m²(p<0.001)。
  • 替尔泊肽组CRP为4.2±3.8 mg/L,对照组为7.7±3.0 mg/L(p<0.001)。
  • PsAID-12 PASS达标率为48% vs 21%(OR 3.44,95%CI 1.38至8.63,p=0.009)。
  • HAQ≤0.5达标率为42% vs 18%(OR 3.27,95%CI 1.26至8.44,p=0.022)。
  • PASI≤1达标率为74% vs 52%(OR 2.59,95%CI 1.03至6.56,p=0.045)。

关键数值与推荐

  • BMI≥30 kg/m²或≥27 kg/m²且至少一种体重相关合并症。
  • DAPSA低疾病活动度定义为≤14。
  • PsAID-12 PASS定义为≤4。
  • HAQ≤0.5,PASI≤1。

临床怎么用

  • 对合并肥胖的PsA患者,在起始生物制剂时可考虑同步启用替尔泊肽以改善患者报告结局、皮肤控制和炎症指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate 6-month clinical outcomes in obese patients with psoriatic arthritis (PsA) who initiated tirzepatide concurrently with biologic therapy compared with those starting biologics alone. METHODS: Propensity score-matched comparative study at tertiary care rheumatology centres. Patients with PsA with body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity initiating tirzepatide (2.5 mg/week, uptitrated to 5 mg/week after 1 month) with biologic therapy were prospectively enrolled from January 2025. Controls initiating biologics alone (2021-2025) were matched 1:2 on BMI, disease duration, Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI). Outcomes at 6 months included minimal disease activity, DAPSA low disease activity (≤14), PsA Impact of Disease-12 (PsAID-12) Patient Acceptable Symptom State (PASS ≤4), Health Assessment Questionnaire (HAQ ≤0.5), PASI ≤1, Visual Analogue Scale pain and C reactive protein (CRP). Continuous outcomes were additionally analysed with ANCOVA adjusted for baseline and a mixed (time × group) model. RESULTS: Thirty-one patients completed 6 months and were matched to 62 controls. Baseline characteristics were well balanced. The tirzepatide group showed greater BMI reduction (-2.9±2.0 vs +0.4±1.2 kg/m², p<0.001) and lower CRP (4.2±3.8 vs 7.7±3.0 mg/L, p<0.001). PsAID-12 PASS was achieved by 48% vs 21% (OR 3.44, 95% CI 1.38 to 8.63, p=0.009), HAQ≤0.5 by 42% vs 18% (OR 3.27, 95% CI 1.26 to 8.44, p=0.022) and PASI≤1 by 74% vs 52% (OR 2.59, 95% CI 1.03 to 6.56, p=0.045). Baseline-adjusted ANCOVA confirmed significant 6-month differences in favour of tirzepatide for BMI, CRP, PsAID-12 and DAPSA, with a significant time × group interaction for BMI, CRP and PsAID-12. CONCLUSION: Concurrent tirzepatide and biologic initiation in obese PsA was associated with significantly better patient-reported outcomes, skin disease control, baseline-adjusted joint disease activity and CRP reduction at 6 months.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Venerito V, Lopalco G, Colaprico C, et al. Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study. RMD Open. 2026. PMID: 42532547. doi:10.1136/rmdopen-2026-006830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。